After up to three years on GA Depot, most people with PPMS have not experienced any disability progression, according to new ...
Scientists at the 2026 ACTRIMS forum meet to assess current approaches and explore new directions for MS research and care.
A small study suggests Mavenclad’s effectiveness in MS may be linked to how regulatory T-cells respond to treatment.
Columnist Ben Hofmeister is now six months into first eliminating, then gradually reintroducing, foods to his diet to manage MS symptoms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results